GALAPAGOS
Manufacturing · Belgium · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Generaal De Wittelaan l11 a3, Mechelen, ...Phone Number
+32 15342900Website
www.glpg.comRevenue
$267.9 MillionStock Symbol
GLPGIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About GALAPAGOS
Galapago is a clinical-stage biotechnology company that specializes in the discovery and development of small molecule medicines. This company is headquartered in Belgium.Explore more
GALAPAGOS Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GALAPAGOS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on GALAPAGOS recently announced quarterly report
Product Launch: Get notified when GALAPAGOS launches new products
Check out if GALAPAGOS is spiking on competitors!
Funding: Get notified immidiatlly once GALAPAGOS has new funding data
Check if GALAPAGOS has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if GALAPAGOS had a recent Job posting/layoffs
GALAPAGOS, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at GALAPAGOS
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
GALAPAGOS is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
GALAPAGOS is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about GALAPAGOS.
GALAPAGOS financials insights
Gather financial insights about GALAPAGOS, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$275.4M
2020
Share Placement
$19.9M
2021
Stock Offering
$178K
GALAPAGOS Tech Stack
A closer look at the technologies used by GALAPAGOS
See more technologies
Most Recent Scoops
Person-Based
Partnership, Product Development, Corporate Strategy
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Executive Moves, Mergers & Acquisitions, Corporate Strategy
Person-Based
Project
Spending/Investment
GALAPAGOS News & Media
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update
Galapagos’ name change to Lakefront Biotherapeutics approved at the Company’s EGM (Euronext & NASDAQ: LKFT) Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026 Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation priorities YearGalapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026
Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 28 April 2026 were approved.Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets
Galapagos NV (NASDAQ:GLPG) is one of the 7 Fastest Growing European Stocks to Invest In. On March 31, 2026, Galapagos NV (NASDAQ:GLPG) announced a binding agreement with Gilead Sciences (NASDAQ:GILD) related to Gilead’s planned acquisition of Ouro Medicines, a U.S.-based biotech focused on T cell engager therapies for autoimmune diseases. The deal includes access to […]Galapagos Partners With Gilead on Gamgertamig, Unlocks $500M Cash and Eyes 2027 Registrational Trials
Galapagos (NASDAQ:GLPG) said it has entered into a binding collaboration agreement with Gilead focused on Gamgertamig, a BCMA x CD3 T-cell engager being developed for autoimmune diseases. Chief Executive Officer Henry Gosebruch said the deal follows “advanced discussions” disclosed the prior week an
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GALAPAGOS
Sign Up For FreeTo access detailed company insights
Galapago is a clinical-stage biotechnology company that specializes in the discovery and development of small molecule medicines. This company is headquartered in Belgium.... Read More
